Graybill Bartz & Assoc Ltd. Reduces Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Graybill Bartz & Assoc Ltd. decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,804 shares of the medical research company’s stock after selling 197 shares during the quarter. Thermo Fisher Scientific makes up approximately 3.1% of Graybill Bartz & Assoc Ltd.’s portfolio, making the stock its 8th largest holding. Graybill Bartz & Assoc Ltd.’s holdings in Thermo Fisher Scientific were worth $4,603,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Hillsdale Investment Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 1,208.8% in the 2nd quarter. Hillsdale Investment Management Inc. now owns 2,225 shares of the medical research company’s stock valued at $654,000 after purchasing an additional 2,055 shares in the last quarter. Clarius Group LLC raised its holdings in shares of Thermo Fisher Scientific by 13.6% in the third quarter. Clarius Group LLC now owns 2,962 shares of the medical research company’s stock valued at $863,000 after buying an additional 355 shares during the last quarter. Cohen Lawrence B raised its holdings in shares of Thermo Fisher Scientific by 2.0% in the second quarter. Cohen Lawrence B now owns 10,185 shares of the medical research company’s stock valued at $2,991,000 after buying an additional 195 shares during the last quarter. Private Trust Co. NA raised its holdings in shares of Thermo Fisher Scientific by 66.7% in the second quarter. Private Trust Co. NA now owns 3,273 shares of the medical research company’s stock valued at $961,000 after buying an additional 1,310 shares during the last quarter. Finally, Amica Retiree Medical Trust raised its holdings in shares of Thermo Fisher Scientific by 8.4% in the second quarter. Amica Retiree Medical Trust now owns 3,184 shares of the medical research company’s stock valued at $935,000 after buying an additional 247 shares during the last quarter. 88.21% of the stock is currently owned by institutional investors.

A number of research analysts recently issued reports on TMO shares. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $315.00 to $330.00 and gave the company an “overweight” rating in a report on Wednesday. Needham & Company LLC lifted their price target on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Credit Suisse Group reaffirmed a “buy” rating and issued a $310.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, July 31st. ValuEngine cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Robert W. Baird lifted their price target on Thermo Fisher Scientific from $305.00 to $319.00 and gave the company an “outperform” rating in a report on Thursday. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and an average price target of $309.92.

In other news, Director Jim P. Manzi sold 1,833 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $272.93, for a total transaction of $500,280.69. Following the completion of the transaction, the director now directly owns 28,592 shares in the company, valued at approximately $7,803,614.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 2,271 shares of the business’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $298.00, for a total value of $676,758.00. Following the transaction, the chief executive officer now owns 283,502 shares of the company’s stock, valued at $84,483,596. The disclosure for this sale can be found here. Insiders have sold a total of 54,104 shares of company stock valued at $15,418,539 over the last 90 days. Corporate insiders own 0.45% of the company’s stock.

Shares of NYSE:TMO opened at $293.44 on Friday. The stock has a market capitalization of $118.91 billion, a P/E ratio of 26.39, a P/E/G ratio of 1.93 and a beta of 1.13. Thermo Fisher Scientific Inc. has a 1-year low of $208.34 and a 1-year high of $305.45. The company has a current ratio of 1.80, a quick ratio of 1.07 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average price of $288.78 and a two-hundred day moving average price of $281.64.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.88 by $0.06. The firm had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.19 billion. Thermo Fisher Scientific had a return on equity of 17.16% and a net margin of 14.24%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.62 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 12.32 EPS for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: Support Level

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.